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doi:10.1016/j.ejvs.2009.11.016Abstract Objectives and Design: We investigated whether immunosuppression was necessary
for transplanted allogeneic veins to adapt to arterialisation. We used a transplant rat model
with or without immunosuppression.
Material and Methods: Iliolumbar veins from Lewis (LEW) or BrowneNorway (BN) rats were
transplanted into the abdominal aorta of isogeneic (LEW to LEW; group A) or allogeneic (BN
to LEW; groups B and C) rats. Group C had daily intramuscular injections of 0.2 mg kg1
FK506. Light microscope evaluations of grafts were performed at 30 days following transplan-
tation. We determined the presence of endothelial cells, the intensity of intimal proliferation
and the degree of infiltration by Lewis major histocompatibility complex (MHC) class II posi-
tive, CD4-positive and CD8-positive cells into the adventitia.
Results: Groups A and C displayed similar results in intimal thickness (12.7  7.0 mm
vs. 15.0 8.4 mm, respectively) and degree of adventitial infiltration by MHC class II posi-
tive (16.6 7.5 vs. 14.6 6.2, respectively), CD8-positive (0.8 1.7 vs. 1.8 2.6, respec-
tively) and CD4-positive (12.5  7.7 vs. 5.8  4.6, respectively) cells. In contrast,
allogeneic rats without immunosuppression (group B) showed infiltration of host immuno-
competent cells and destruction of the venous wall with no histological signs of
arterialisation.
Conclusion: Immunosuppressive therapy is necessary for venous allograft adaptation to ar-
terialisation in rats.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights
reserved.ting 3e6 September, 2009, European Society for Vascular Surgery, Oslo, Norway.
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FK506 After Allovenous Transplantation in Rats 479Vascular peripheral reconstructive surgery involves the
interposition of an autologous vein into the arterial circu-
latory tree. This results in an adaptation of the venous wall
to the new biomechanical conditions.1 Vein remodelling is
a complex biological process that requires alterations in
cell proliferation, cell death, cell migration and degrada-
tion and/or production of extracellular matrix compo-
nents.2 These adaptive interactions amongst vascular cells,
their substrates and the local environment lead to the
typical anatomical changes associated with venous arteri-
alisation: intimal hyperplasia, circumferential medial
thickening with well-organised concentric layers of smooth
muscle cells and adventitial neovascularisation.1,3
In specific indications, allogeneic veins are used for
peripheral vascular reconstruction in humans.4,5 Immuno-
logical studies have shown that venous allografts that had
been cold-stored or cryopreserved were antigenic and eli-
cited an immune response in the recipient.6e8 Allovenous
wall rejection could play an important role in the low
patency rates of venous allografts. Currently, low patency is
the primary limitation of venous allografts for clinical use.5,9
Different types of immunosuppressive drugs have been
examined as possible adjuncts for reducing antigenicity and
improving the patency rates of venous allografts, but these
studies have shown different results in animals and
humans.9e12 Currently, immunosuppressive therapy
following allovenous reconstruction is generally not
accepted in clinical practice.
FK506 (tacrolimus) is a modern immunosuppressive drug
that belongs to the group of calcineurin inhibitors. One of
its most important immunosuppressant effects is the inhi-
bition of interleukin-2 (IL-2)-dependent T-cell activation.13
FK506 is routinely used clinically, in combination with other
types of immunosuppressive drugs, to inhibit immune
responses following renal and liver transplantations.14 In
previous studies, we confirmed the positive effect of FK506
administration on arterial transplantation. FK506 inhibited
wall destruction in the abdominal aorta caused by acute
rejection, assessed 30 days following transplantation into
the rat arterial system.15
This study aimed to investigate the process of allovenous
arterialisation under conditions of FK506 immunosuppres-
sion. Because medial smooth muscle cell proliferation is
a dominant feature of the venous arterialisation process,
we hypothesised that immunosuppression would, to some
degree, preserve smooth muscle cell content in allografted
veins, and that smooth muscle cell preservation would be
necessary for successful allovenous arterialisation.
Material and Methods
Principles of laboratory animal care were followed, and
applicable national laws observed during the study. Ethical
approval by local ethical committee was obtained for this
study.
Animals
Male Lewis rats (LEW) (RT1l) in the weight range of 200e
340 g (NZ 26) were used as recipients of allogeneic or
syngeneic iliolumbar vein grafts and male BrowneNorwayrats (BN) (RT1n) in the weight range of 220e300 g (NZ 9)
were used as donors for the allogeneic group, and LEW
(RT1l) in the weight range of 280e300 g (NZ 5) were used
as donors for the syngeneic group. Animals were obtained
from Charles River, Germany. All the rats were maintained
according to the National Institute of Health guidelines.
Each transplanted animal was housed in a separate cage
during the entire 30-day follow-up period.
Operative procedures
The donor animals were anaesthetised with an intramus-
cular injection of ketamine (Narkamon, Spofa a.s., Pra-
gue, Czech Republic) at a dose of 100 mg kg1 and xylazine
(Rometar, Spofa a.s., Prague, Czech Republic) at
10 mg kg1. Two 1e1.5-cm long segments of the iliolumbar
veins were excised and these excised veins were stored in
saline solution at room temperature until transplantation.
The mean ischaemic time for iliolumbar venous grafts
during the entire experiment was 201 103 min, with no
significant statistical differences amongst the experimental
groups (Table 1).
Animals that were used as recipients of venous grafts
with planned follow-up were given less invasive anaesthesia
to ensure more natural awakening. The recipients were
anaesthetised with an intramuscular injection of sufentanil
(Sufenta, Janssen Pharmaceutica Inc., Beerse, Belgium) at
20 mg kg1 and azaperone (Stresnil, Janssen Pharmaceutica
Inc., Beerse, Belgium) at 1 mg kg1. Following a midline
laparotomy into the recipient’s infrarenal aorta, the venous
grafts were transplanted with a running 10/0 mono-filament
suture (Ethicon Inc., Sommerville, NJ, USA).
Neither anticoagulants nor anti-platelet drugs were
administrated during the harvest, operative time or in the
postoperative period.
Animal groups
The recipient animals were divided into three groups.
Groups A and B comprised rats that received isogeneic (LEW
to LEW) and allogeneic (BN to LEW) venous trans-
plantations, respectively. Neither group was given immu-
nosuppression. Group C comprised rats that received
allogeneic venous transplantations (BN to LEW) and were
given immunosuppression (Table 1).
Immunosuppressive therapy
FK506 (Prograf, Astellas Pharma Inc., Tokyo, Japan) was
the immunosuppressive drug given to the recipient animals
in group C. FK506 was suspended in normal saline solution
and administered intramuscularly in daily doses of
0.2 mg kg1. On day 30, following transplantation, blood
levels of FK506 were evaluated with an enzyme-enhanced
immunoassay technique (Emit 2000 Tacrolimus assay,
Dade Behring Inc., Deerfield, IL, USA). The blood was drawn
from infrarenal vena cava punctured prior to euthanasia.
On day 30, anaesthetised, heparinised animals in all
experimental groups received a midline re-laparotomy to
remove the venous grafts. The animals were then euthan-
ised by intracaval administration of a lethal dose of
Table 1 Basic characteristics of each experimental group and operative procedures.


















A LEW to LEW no 8 2 215 138 130 19 79 8 223 21 295 17 no
B BN to LEW no 10 1 199 85 115 13 66 10 317 18 366 25 no
C BN to LEW FK506 8 1 190 85 100 14 75 9 275 20 305 16 5.57 0.96
LEW, male Lewis rats; BN, male BrowneNorway rats; CIT, cold ischaemic time; OP time, duration of operation.
a The mean cold ischaemic time (CIT) of iliolumbar venous grafts was with no statistical difference between all the experimental
groups (Group A vs. Group B pZ 0.46, Group A vs. Group C pZ 0.59, Group B vs. Group C pZ 0.42).
480 I. Matia et al.thiopental (Thiopental, Spofa a.s., Prague, Czech
Republic). The removed grafts were processed for histology
and immunohistochemistry.
Histology and immunohistochemistry
Histological and immunohistochemical analyses of venous
grafts were performed according to methods described
previously for our arterial transplantation model.15 Briefly,
the venous grafts were embedded in Sakura Finetek Tissue
Tekª Cryomold holders (Sakura Finetek, Tokyo, Japan) and
Sakura Finetek Tissue Tekª O.C.T. compound (Sakura
Finetek, Tokyo, Japan). The samples were subsequently
frozen in 2-methylbutane (Fluka Chemika, Buchs,
Switzerland) cooled by liquid nitrogen and then stored at
80 C.
Histological analysis
The samples obtained were cut into 5-mm sections and
stained with HaematoxylineEosin and a Van Gieson with
elastica stain. The sections were taken from the mid-
portion of the graft to avoid tissue that may have reacted to
the suture material. Each section was photographed with
an Olympus Cammedia C-5050 digital camera (Olympus,
Hamburg, Germany) mounted on an Olympus BX51 micro-
scope at a magnification of 400. The images were digitally
captured in TIFF format with no compression and analysed
with Olympus DP-Soft software Version 3.2. Intimal thick-
ness was measured from the endothelial surface to the
inner border of the tunica media. Measurements were
made in up to 10 locations in each section. The mean value
and standard deviation (mean SD) were calculated for
each vein and each animal group.
Immunohistochemical analysis
Information on the antibodies used for all immunohisto-
chemical analyses is shown in Table 2.Table 2 The list of monoclonal and polyclonal antibodies used f
Specificity Origin Company
Von Willebrand factor Rabbit DakoCytomation
CD4þ cells Mouse Cymbus Biotechnol
CD8þ cells Mouse Cymbus Biotechnol
RT1.Bu a Mouse Cedar Lane
a Major histocompatibility complex class II positive cells of host origDetection of CD4D cells, CD8D cells and Von Willebrand
factor
Immunohistochemistry was performed on 8-mm-thick
sections with a two-step indirect method. Briefly, the
sections were fixed in cold acetone for 10 min. After rinsing
in 0.2% Triton X100 and phosphate-buffered saline, the
specimens were incubated with a primary antibody for
60 min. Endogenous peroxidase was blocked by incubating
in 0.3% hydrogen peroxide (H2O2) and 70% methanol for
30 min. Next, the sections were incubated with a secondary
antibody (Histofine Simple Stain Rat MAX PO, Nichirei,
Japan) for 30 min, then incubated with Dako Liquid DABþ
Substrate-Chromogen System (Dako Denmark A/S,
Glostrup, Denmark) for 5 min. The specimens were coun-
terstained and dipped in Entellanª (Merck KGaA, Darm-
stadt, Germany).
The slides were then scored in a blinded fashion. Cells
were counted at five locations at 1000 magnification. The
cellularity was defined as the mean value of the cells
counted.
Detection of Lewis MHC class II positive cells
Immunohistochemistry was performed on 8-mm-thick
sections with a three-step indirect method. Briefly, the
sections were fixed for 10 min in cold acetone. After
sections were rinsed in 0.2% Triton X100 and phosphate-
buffered saline, endogenous biotin was blocked with the
biotin-blocking system (Dako Denmark A/S, Glostrup,
Denmark). The tissues were then incubated in 10% horse
serum to prevent non-specific binding, and then a primary
antibody was applied for 60 min. Then, endogenous
peroxidase was blocked in 0.3% H2O2 and 70% methanol for
30 min. The specimen was incubated with a secondary
biotinylated horse anti-mouse antibody (Vector Lab, Bur-
lingame, CA, USA), followed by an incubation with R.T.U.
Vectastain Elite ABC Reagent (Vector Lab, Burlingame, CA,
USA). Finally, specimens were incubated for 5 min with
Dako Liquid DABþ Substrate-Chromogen System (Dako
Denmark A/S, Glostrup, Denmark), counterstained and
dipped in Entellan (Merck KGaA, Darmstadt, Germany).or immunohistochemical staining of iliolumbar venous grafts.
Dilution Clone Detection
5000x Histofine
ogy LTD 800x W3/25 Histofine
ogy LTD 500x OX-8 Histofine
50x MRC-OX3 Vector
in.
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The values in the text and figures are expressed as the
mean  standard deviation (SD). Comparisons of intimal
thicknesses and numbers of lymphocytes and Lewis MHC
class II positive cells between the experimental groups
were performed with the analysis of variance (ANOVA)
method, followed by the Tukey HSD Multiple Comparisons
test. The p values < 0.05 were considered significant.
Results
Animals
A total of 30 LEWs were intended for transplantations, but
only 26 survived the procedure. Four animals died during
the experiment. Three died due to perioperative bleeding
(two from group A and one from group B) and one animal
was overdosed with anaesthetics (group C). The increase in
fatal bleeding in the group A, compared to the other
groups, was due to technical failures, which arose initially
(and this group was operated at the start of the
experiment).
An increase from preoperative weight was observed in
all groups at 30 days. The percentage weight increase was
significantly higher (p< 0.01) in the syngeneic group A
compared to both allogeneic groups. This was probably dueFigure 1 Representative light microscopic histological features
(group B) rat venous allografts obtained at 30 days following trans
arterialisation in allogeneic immunosuppressed venous grafts was
plasia and formation of elastic tissue laminae in the neointima (la
black arrows); (C2) (Von Willebrand factor positive cells) endothe
monolayer of endothelial cells) and (C3) (Lewis MHC class II positiv
(adventitial layer is marked with black arrows). In allogeneic non-im
immunocompetent cells led to tissue rejection. (B1, B3) (Van Gi
organisation of the allovenous wall structure is evident with no sign
(B2) (Von Willebrand factor positive cells) the luminal surface of d
(black arrows show the monolayer of endothelial cells). Magnificatto the lower weight of animals in syngeneic group A on day
0 when compared to both allogeneic groups (Table 1).
Immunosuppression
The mean blood level of FK506, measured on day 30 after
transplantation, in group C was 5.57 0.96 ngml1. Diar-
rhoea was an adverse effect of FK506 administration, and it
was observed in five out of seven animals in the immuno-
suppressed group C.
Graft patency
No venous graft thromboses or occlusions were observed in
any of the animals on day 30 following transplantation.
Tunica intima
In all groups, at 30 days following transplantation, the
luminal surface of the venous allograft was covered by
a monolayer of endothelial cells. In immunosuppressed
iliolumbar vein allografts, hyperplasia of the subendothelial
neointima developed during that period. The neointima
was formed primarily from elastic tissue (Fig. 1). The same
feature was observed in syngeneic arterialised venous
grafts of group A. The intima thicknesses did not differ
between these two experimental groups (Table 3).of immunosuppressed (group C) and non-immunosuppressed
plantation into the infrarenal abdominal aorta. The process of
represented by: (C1) (Van Gieson with elastica) intimal hyper-
yer of smooth muscle cells in the tunica media is marked with
lialisation of the luminal surface (black arrows show positive
e cells) low adventitial infiltration of immunocompetent cells
munosuppressed venous grafts, massive infiltration of the host
eson with elastica, Lewis MHC class II positive cells) the dis-
s of arterialisation (venous wall is marked by black arrows) and
isorganised venous allografts was covered by endothelial cells
ionZ100.
Table 3 Assessments of rat iliolumbar venous grafts 30 days after transplantation into the abdominal aorta. IS e
immunosuppression.







CD8þ cells CD4þ cells
A LEW to LEW no 12.7 7.0 þ þ 16.6 7.5 0.8 1.7 12.5 7.7
B BN to LEW no 2.2 0.7a þ  99.9 24.9b 24.1 14.0b 42.7 20.0b
C BN to LEW FK506 15.0 8.4 þ þ 14.6 6.2 1.8 2.6 5.8 4.6c
a Intimal thicknesses of non-immunosuppressed venous allografts (group B) were statistically lower (P< 0.01) than that observed in
both the other groups (A and C).
b The total amounts of Lewis MHC class II positive, CD8-positive, and CD4-positive cells in group B were significantly higher (P< 0.001)
than those observed in both the other groups (A and C).
c The total amount of CD4-positive cells in immunosuppressed allogeneic veins (group C) was significantly lower (P< 0.01) than that
found in the isogeneic group A.
d Intimal thicknesses are expressed in mm.
e Numbers of Lewis MHC class II, CD8-positive, and CD4-positive cells in one microscopic field viewed at a magnification of 1000.
f Major histocompatibility complex class II positive cells of host origin.
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lumbar vein grafts (group B) resulted in the destruction of
the intima and disorganisation of the whole venous wall
structure. Minimal or no signs were observed of elastic
tissue formation in this layer when compared to syngeneic
or immunosuppressed venous grafts (Fig. 1). However, this
elastic tissue formation was not quantified. The intimal
thickness was statistically lower in venous allografts
without immunosuppression than in venous allografts with
immunosuppression (p< 0.01) (Fig. 2).
Tunica media
In immunosuppressed venous allografts, the process of
adaptation to arterial pressure led to the formation of
multiple smooth muscle layers at 30 days following trans-
plantation. Minimal or no infiltration of host MHC class II,
CD4-positive and CD8-positive cells was observed in the
medial layer of immunosuppressed venous allografts. TheseFigure 2 Intimal proliferation at 30 days following trans-
plantation did not differ between syngeneic venous grafts
(group A) and allogeneic immunosuppressed venous grafts
(group C). The intimal thickness in allogeneic non-immuno-
suppressed venous grafts (group B) was significantly lower
(P< 0.01) compared to both groups A and C.histological signs of venous arterialisation were identical to
those observed in syngeneic venous grafts (Fig. 1).
In contrast, no typical concentric smooth muscle layers
were observed in non-immunosuppressed allogeneic venous
grafts at 30 days following transplantation. Furthermore,
the medial layer was infiltrated with all types of host
immunocompetent cells in these allografts (Fig. 1).
Tunica adventitia
In immunosuppressed venous allografts on day 30 the
adventitial layer was characterised by the infiltration by
mononuclear cells (Fig. 1). Moreover, adventitial infiltra-
tion of CD4þ cells was significantly lower in immunosup-
pressed allogeneic animals (p< 0.01) compared to that
observed in isogeneic grafts. However, the degree of
adventitial infiltration by CD8þ and Lewis MHC class
II þ cells was comparable in immunosuppressed allogeneic
and syngeneic arterialised veins (Table 3).
In non-immunosuppressed venous allografts, tissue
rejection led to massive wall infiltration by immunocom-
petent cells (Fig. 1). The total amounts of CD4þ, CD8þ and
host MHC class II positive cells that infiltrated the adven-
titial layer in the absence of immunosuppression were
significantly higher (p< 0.001) than those observed in
immunosuppressed allogeneic veins (Table 3).
Discussion
The present study examined the morphological changes of
venous allografts implanted into the arterial system of rats.
The results revealed that immunosuppression was neces-
sary for the development of venous wall adaptation to
arterial pressure within 30 days of transplantation. The
suppression of the recipient immune response in the early
post-transplantation phase led to the preservation of
venous smooth muscle cells in transplanted veins. The
presence and subsequent proliferation of these smooth
muscle cells contributed to an increase in vascular wall
thickness and mass, the typical features of venous arteri-
alisation observed in syngeneic conditions.1
FK506 After Allovenous Transplantation in Rats 483In the absence of immunosuppression, allogeneic
venous grafts were unable to develop the typical signs of
venous wall arterialisation. Allogeneic smooth muscle
cells were destroyed by massive infiltration of immuno-
competent cells and were not able to proliferate or adapt
to the new biomechanical conditions in the arterial
system.
There are two principal animal models described in the
literature for studying the process of arterialisation in vivo.
The first one, which was also used in this study, generates
neointimal hyperplastic lesions and is performed by the
dissection, removal and storage of vessels prior to inter-
position into the arterial circulatory system.3,16 The second
one, first described by Kwei et al.,1 connects the animal’s
external jugular vein to the carotid arterial circulation in
situ (arterio-venous connection). Thus, the arterialised
venous segment is never exteriorised from the body of the
animal. The main difference between these models is
the status of endothelial and smooth muscle cells at the
beginning of the remodelling process.1 In the ‘in situ
model’, at 7 days post-surgery, the intact endothelial layer
promoted the proliferation of smooth muscle cells, the
formation of smooth muscle cell layers and caused minimal
apoptosis in the vascular wall;1 however, the ‘ex situ
model’, at 7 days, showed significant cell loss and vessel
degeneration. This resulted secondary to increased tensile
stress following exposure to arterial blood pressure, vessel-
wall ischaemia and free-radical oxidative injury associated
with reperfusion.3,16 In the ex situ model, venous wall cell
death occurred early, following implantation, both by
necrosis and apoptosis. This was soon replaced by cellular
proliferation in the adventitia and the tunica media. This
resulted in increased microvessel density and smooth
muscle cell regeneration during the first week.3 Neointimal
formation took place thereafter.3
Because ischaemicereperfusion injury is inevitable in
venous transplantation, all the venous grafts in our exper-
iment were damaged at implantation. We assumed there
were no differences in damage between the groups,
because all groups had similar cold ischaemic times.
However, smooth muscle cell regeneration and prolifera-
tion, followed by neointimal hyperplasia, were only
possible in allogeneic venous grafts with immunosuppres-
sion. Without immunosuppression, allogeneic venous grafts
exhibited massive infiltration by immunocompetent cells
and destruction of the venous wall.
In this study, we used FK506 for immunosuppression,
which is more potent than cyclosporine A.14 In other
studies, a combination of cyclosporine A and mycopheno-
late mofetil was used in dogs following allogeneic venous
transplantation.11 They found a 100% patency rate at 20
weeks after implantation and immune reactions were
markedly reduced. However, given alone, neither cyclo-
sporine A at a 10 mg kg1 per day nor mycophenolate
mofetil at 20 mg kg1 per day improved the overall patency
of venous allografts. In the work of Mingoli et al.,10 cyclo-
sporine A at 20 mg kg1 day reduced aneurysmal dilatation
and immunological responses at 30 days following alloge-
neic venous transplantations in dogs. However, dis-
continuing cyclosporine A immunosuppression led to the
occlusion of cold-stored17 as well as cryopreserved18 venous
allografts within 30 days.Other studies have reported on the therapeutic poten-
tial of immunosuppression for the treatment of vein graft
disease in syngeneic vein-to-artery implantations. Schach-
ner et al.19 demonstrated reduced intimal thickness and
decreased inflammatory cell infiltration following peri-
vascular application of rapamycin in a mouse model. This
reduction of vein graft disease was associated with
a decreased amount of CD8þ cell infiltration. In our model,
we found no differences in the adventitial CD8þ cellular
infiltration between syngeneic grafts and allogeneic
immunosuppressed grafts. Moreover, the extent of intimal
proliferation in immunosuppressed allografts was compa-
rable to that observed in syngeneic grafts.
Immunosuppressive therapy following allovenous recon-
structions is not generally accepted in clinical practice,
despite experimental10 and clinical7 evidence of the
potential benefits. We believe that inhibition of rejection
and reduced destruction of the allogeneic venous wall with
low systemic immunosuppression could improve the low
patency rate of allogeneic transplantation. In our clinical
practice, we have given this drug to patients with allove-
nous or alloarterial grafts at a mean daily dosage of 2 mg,
which resulted in mean blood levels of 5 ngml1. We found
no or minimal adverse effects associated with this immu-
nosuppressive regimen in a small, but high-risk, group of
vascular patients.5 However, a controlled prospective
clinical study is needed to investigate the impact of this
immunosuppressive regimen on the patency rates of allo-
venous grafts.
In conclusion, the present study considered the positive
effect of FK506 immunosuppression on the wall-remodel-
ling process of venous allografts following implantation into
the arterial system in rats. We suggest that the principal
effects of FK506 under these conditions were the suppres-
sion of CD8þ infiltration in the venous adventitial layer and
the prevention of vascular smooth muscle cell depletion.
The use of FK506 in clinical venous allotransplantation
could be potentionally beneficial for increasing of the
allovenous bypasses patency rates by the inhibition of
venous wall destruction by the host’s immune system.
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